Silexion Therapeutics's total assets for Q3 2025 were $11.61M, a decrease of ― from the previous quarter. SLXN total liabilities were $4.64M for the fiscal quarter, a ― a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.